Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Intensity Therapeutics (INTS) Stock Price, News & Analysis

Intensity Therapeutics logo

About Intensity Therapeutics Stock (NASDAQ:INTS)

Key Stats

Today's Range
$2.36
$2.79
50-Day Range
N/A
52-Week Range
$0.26
$4.94
Volume
73,559 shs
Average Volume
2.93 million shs
Market Capitalization
$11.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Buy

Company Overview

Intensity Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

INTS MarketRank™: 

Intensity Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 578th out of 743 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Intensity Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Intensity Therapeutics has a consensus price target of $4.50, representing about 1,759.5% upside from its current price of $0.24.

  • Amount of Analyst Coverage

    Intensity Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Intensity Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Intensity Therapeutics are expected to grow in the coming year, from ($1.18) to ($1.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Intensity Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Intensity Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Intensity Therapeutics has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.65% of the float of Intensity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Intensity Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Intensity Therapeutics has recently decreased by 32.09%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Intensity Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Intensity Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.65% of the float of Intensity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Intensity Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Intensity Therapeutics has recently decreased by 32.09%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Intensity Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    13 people have searched for INTS on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Intensity Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.10% of the stock of Intensity Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 3.74% of the stock of Intensity Therapeutics is held by institutions.

  • Read more about Intensity Therapeutics' insider trading history.
Receive INTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intensity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INTS Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
See More Headlines

INTS Stock Analysis - Frequently Asked Questions

Intensity Therapeutics Inc. (NASDAQ:INTS) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.13) EPS for the quarter.

Intensity Therapeutics (INTS) raised $20 million in an initial public offering (IPO) on Friday, June 30th 2023. The company issued 3,900,000 shares at a price of $5.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ).

Company Calendar

Last Earnings
8/07/2025
Today
9/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
N/A
Current Symbol
NASDAQ:INTS
CIK
1567264
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

High Price Target
$8.50
Low Price Target
$1.50
Potential Upside/Downside
+1,759.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.27 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-612.44%
Return on Assets
-287.43%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
1.40
Quick Ratio
1.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.19 per share
Price / Book
1.27

Miscellaneous

Outstanding Shares
49,060,000
Free Float
45,572,000
Market Cap
$11.87 million
Optionable
Not Optionable
Beta
3.25
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:INTS) was last updated on 9/29/2025 by MarketBeat.com Staff
From Our Partners